Your AI-Trained Oncology Knowledge Connection!
Opinion
Video
Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC
Panelists discuss how, in clinical practice, ADAURA (osimertinib) and ALINA (alectinib) are integrated based on EGFR/ALK status, stage, and recurrence risk. Adjuvant therapy duration is typically 3 years. Circulating tumor DNA (ctDNA), minimal residual disease (MRD) from ADAURA (ASCO 2024, Abs 8005) may refine treatment decisions by detecting MRD.
Video content above is prompted by the following:
- How are you incorporating the ADAURA and ALINA regimens into your clinical practice, and what factors influence your patient selection?
- What is your anticipated duration of therapy for patients receiving adjuvant osimertinib or alectinib?
- What is the role of ctDNA in early-stage NSCLC, and how may it guide adjuvant therapy decisions? (MRD analysis from ADAURA: John T, ASCO 2024. Abs 8005.
Related Videos
Related Content
